We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Roche Sells Genome Sequencer 20 to DYN


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche Sells Genome Sequencer 20 to DYN"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

DYN G.S. Ltd, located at the Sheba medical center in Israel, has announced that it will establish a center for sequencing services and post-sequencing analysis.

Company has purchased Genome Sequencer 20 System from Roche Applied Science.

DYN G.S. is aiming to become a specialized center for providing sequencing services, focused on the 454 technology, and post-sequencing analysis turning the data to applicable scientific knowledge, cultivating advanced applications for medical diagnostics and research practice.

Their lab was planned according to the 454 and Roche Diagnostics requirements.

Each step of the sequencing protocol is performed in a seprate room with a high level of contamination precautions.

The company supports all the applications available from 454 and Roche Diagnostics, including whole genome sequencing, Paired-End, Amplicon, etc., and provides a tailor-made service according to their customers’ requirements.

Furthermore, DYN invests efforts in acquiring applications’ know-how and assigning them on the Genome Sequencer 20 System and is open to cooperation and collaborations.

"For us, the Genome Sequencer 20 System provides a rapid and efficient solution for sequencing of genomes," stated Dr. Relly Forer, DYN G.S. Ltd manager.

"We join the front line of Genomics by using this revolutionary technology and learn more about the future."

"Although we as supplier of the Genome Sequencer 20 System have foreseen a big demand for this innovative system, we are surprised how fast the market is developing," said Manfred Baier, Head of Roche Applied Science.

"The substantial reductions in both time and costs by using the system offer the prospect of new applications for sequencing in the fields of whole genome sequencing, transcriptome and gene regulation studies, or amplicon analysis e.g., as a basis for the detection of somatic mutations in cancer samples."

For post-sequencing analysis - assembling the reads, mapping the reads to a reference sequence, detecting the genes and assigning function to them, and revealing a global and local interpretation of the data - DYN G.S. will use their own bioinformatics.

Their bioinformatics utilizes a collection of proven programs to annotate the sequence information along with an interface to browse, query and produce reports.

All the data is submitted to the customer in a user-friendly media, including: quality scores, raw-data reads assembly or mapping analyses, functional annotation and further analysis as required.

Advertisement